Claims for Patent: 8,344,018
✉ Email this page to a colleague
Summary for Patent: 8,344,018
Title: | Oxindolyl inhibitor compounds |
Abstract: | A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. (Formula should be inserted here) Formula (I) ##STR00001## |
Inventor(s): | Graupe; Michael (Pacifica, CA), Venkataramani; Chandrasekar (Redwood City, CA) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Application Number: | 12/997,487 |
Patent Claims: | 1. A compound selected from those of Formula (I) and pharmaceutically acceptable salts thereof: ##STR00564## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently
selected from the group consisting of H, halo, nitro, cyano, hydroxy, hydroxyalkyl, haloalkyl, haloalkoxy, amino, aminoalkyl, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy,
C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N-(C.sub.1-10 alkyl)amino, N-(heterocyclyl C.sub.1-10 alkyl)amino, N,N-(C.sub.1-10 alkyl).sub.2-amino, C.sub.1-10 alkanoylamino, N-(C.sub.1-10 alkyl)carbamoyl, N,N-(C.sub.1-10 alkyl).sub.2-carbamoyl,
C.sub.1-10 alkyl-S(O), wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, N-(C.sub.1-10 alkyl)sulphamoyl, N,N-(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, cycloalkyl, cycloalkyloxy,
heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio; wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is optionally substituted by one or more A, or R.sup.3 and R.sup.4 are as defined above, and R.sup.1 and R.sup.2 together
form a cyclic moiety to make a fused ring together with the oxindole ring drawn in Formula (I), wherein the cyclic moiety optionally contains one or more heteroatom selected from N, O and S and the cyclic moiety itself is optionally substituted by one or
more substituents selected from R.sup.1, R.sup.2, R.sup.3 and R.sup.4 groups, each of which is optionally substituted by one or more A; or R.sup.1 and R.sup.4 are as defined above, and R.sup.2 and R.sup.3 together form a cyclic moiety to make a fused
ring together with the oxindole ring drawn in Formula (I), wherein the cyclic moiety optionally contains one or more heteroatom selected from N, O and S and the cyclic moiety itself is optionally substituted by one or more substituents selected from
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 groups, each of which is optionally substituted by one or more A; R.sup.5 is selected from the group consisting of H, halo, haloalkyl, amino, C.sub.1-10 alkyl, N--(C.sub.1-10 alkyl)amino and N,N-(C.sub.1-10
alkyl).sub.2 amino, alkoxyalkyl, alkylaminoalkyl, and cycloalkyl, wherein R.sup.5 is optionally substituted by one or more B; X is phenyl, 5-membered heteroaryl, or 6-membered heteroaryl, wherein the heteroaryl contains one or more heteroatoms selected
from N, S and O; R.sup.6 represents one or more non-hydrogen substituents selected from halo and methyl; n is 0, 1, 2, 3, or 4; R.sup.7 is hydroxy, aryl or heteroaryl, wherein aryl or heteroaryl are substituted with --NH.sub.2 or --OH and aryl or
heteroaryl is optionally further substituted with one or more groups selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further
substituted with one or more groups selected from halo, hydroxy, alkyl, haloalkyl and cycloalkyl; R.sup.8 is H, alkyl, alkanoyl, or cycloalkyl; and A and B are independently selected from halo, nitro, cyano, hydroxy, hydroxyalkyl, haloalkyl,
haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, oxo, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkoxyalkyl, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N-(heterocyclyl C.sub.1-10
alkyl)amino, N-(C.sub.1-10 alkyl)amino, N,N-(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N-(C.sub.1-10 alkyl)carbamoyl, N,N-(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl,
N-(C.sub.1-10 alkyl)sulphamoyl, N,N-(C.sub.1-10 alkyl).sub.2sulphamoyl, H.sub.2NS(O).sub.2NH--, N-(C.sub.1-10 alkyl)NHS(O).sub.2NH--, N,N-(C.sub.1-10 alkyl).sub.2NS(O).sub.2NH--, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, cycloalkyl,
cycloalkyloxy, heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio.
2. The compound of claim 1, wherein at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are hydrogen and each non-hydrogen R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is selected from chloro, fluoro, bromo, methyl, ethyl, propyl, methoxy, ethoxy, acetyl, carboxyl, methylcarboxyl, cyano, methoxymethyl, ethoxyethyl, propoxyethyl, methoxyethoxy, trifluoromethyl, hydroxyethoxy, dimethylamino, diethylamino, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, dimethylaminoethoxy, dimethylaminocarbonyl, dimethylaminoethylamide, trifluoromethoxymethyl, trifluoroethoxymethyl, isopropylcarbonyl, 1-hydroxyethyl, 3-oxetanoxy, trifluoroethylaminomethyl, N-methyl-N-methoxyethyl-aminomethyl, cyclopropanylmethyl, cyclopropyl, cyclobutoxy, 1-cyclopropanylethoxy, cyclopropanylmethylaminomethyl, 4-methylpiperazin-1-carbonyl, isoindolin-2-yl, N-methoxyethylcarbamoyl, N-(morpholin-4-yl)-ethylcarbamoyl, dimethylaminoethylamino, N,N-dimethylaminoethylcarbamoyl, benzyl, phenylethyl, trifluoromethylphenylethyl, phenoxymethyl, fluorophenoxymethyl, phenylethylaminomethyl, benzylaminomethyl, triazinylmethyl, piperidinylmethyl, piperidinyloxy, trifluoromethylpiperidinylmethyl, pyridinyloxymethyl, pyridinylmethoxy, tetrahydropyrazinyloxy, methylpiperazinylmethyl, methanesulfonyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, pyrrolidin-1-ylethoxy, pyrrolidin-2-ylethoxy, pyrrolidin-3-ylethoxy, thiazol-4-yl, 2-methyl-thiazol-4-yl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-4-ylmethyl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, imidazolidin-1-ylmethyl, imidazolidin-2-ylmethyl, imidazolidin-4-ylmethyl, imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolin-1-yl, pyrazolin-3-yl, pyrazolin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-ylmethyl, piperidin-2-ylmethyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-2-ylmethyl, morpholin-3-ylmethyl, morpholin-4-ylmethyl, morpholin-4-ylsulfonyl, morpholin-2-ylethoxy, morpholin-3-ylethoxy and morpholin-4-ylethoxy; R.sup.5 is H, methyl, ethyl or trifluoromethyl; and X is phenyl or 5-membered heteroaryl. 3. The compound of claim 1 selected from those of Formula (I-a) and pharmaceutically acceptable salts thereof: ##STR00565## 4. The compound of claim 3, wherein at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H, and each non-hydrogen R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from chloro, fluoro, bromo, methyl, ethyl, propyl, methoxy, ethoxy, acetyl, carboxyl, methylcarboxyl, cyano, methoxymethyl, ethoxyethyl, propoxyethyl, methoxyethoxy, trifluoromethyl, hydroxyethoxy, dimethylamino, diethylamino, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, dimethylaminoethoxy, dimethylaminocarbonyl, dimethylaminoethylamide, trifluoromethoxymethyl, trifluoroethoxymethyl, isopropylcarbonyl, 1-hydroxyethyl, 3-oxetanoxy, trifluoroethylaminomethyl, N-methyl-N-methoxyethyl-aminomethyl, cyclopropanylmethyl, cyclopropyl, cyclobutoxy, 1-cyclopropanylethoxy, cyclopropanylmethylaminomethyl, 4-methylpiperazin-1-carbonyl, isoindolin-2-yl, N-methoxyethylcarbamoyl, N-(morpholin-4-yl)-ethylcarbamoyl, dimethylaminoethylamino, N,N-dimethylaminoethylcarbamoyl, benzyl, phenylethyl, trifluoromethylphenylethyl, phenoxymethyl, fluorophenoxymethyl, phenylethylaminomethyl, benzylaminomethyl, triazinylmethyl, piperidinylmethyl, piperidinyloxy, trifluoromethylpiperidinylmethyl, pyridinyloxymethyl, pyridinylmethoxy, tetrahydropyrazinyloxy, methylpiperazinylmethyl, methanesulfonyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, pyrrolidin-1-ylethoxy, pyrrolidin-2-ylethoxy, pyrrolidin-3-ylethoxy, thiazol-4-yl, 2-methyl-thiazol-4-yl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-4-ylmethyl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, imidazolidin-1-ylmethyl, imidazolidin-2-ylmethyl, imidazolidin-4-ylmethyl, imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolin-1-yl, pyrazolin-3-yl, pyrazolin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-ylmethyl, piperidin-2-ylmethyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-2-ylmethyl, morpholin-3-ylmethyl, morpholin-4-ylmethyl, morpholin-4-ylsulfonyl, morpholin-2-ylethoxy, morpholin-3-ylethoxy and morpholin-4-ylethoxy; R.sup.5 is H, alkyl or haloalkyl; R.sup.6 is fluoro, chloro, bromo, or methyl and n is 0 or 1; and R.sup.7 is hydroxyl, aryl or heteroaryl, wherein aryl or heteroaryl are substituted with --NH.sub.2 or --OH at a ring position adjacent to attachment of the --CONH-moiety, and R.sup.7 is optionally further substituted with one or more groups selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxy, alkyl, haloalkyl and cycloalkyl. 5. The compound of claim 3 which is selected from the group consisting of: ##STR00566## ##STR00567## ##STR00568## and pharmaceutically acceptable salts thereof. 6. The compound of claim 3 which is selected from the group consisting of: ##STR00569## ##STR00570## and pharmaceutically acceptable salts thereof. 7. The compound of claim 1 selected from those of Formula (I-b) and pharmaceutically acceptable salts thereof: ##STR00571## 8. The compound of claim 7, wherein at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H, and each non-hydrogen R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from chloro, fluoro, bromo, methyl, ethyl, propyl, methoxy, ethoxy, acetyl, carboxyl, methylcarboxyl, cyano, methoxymethyl, ethoxyethyl, propoxyethyl, methoxyethoxy, trifluoromethyl, hydroxyethoxy, dimethylamino, diethylamino, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, dimethylaminoethoxy, dimethylaminocarbonyl, dimethylaminoethylamide, trifluoromethoxymethyl, trifluoroethoxymethyl, isopropylcarbonyl, 1-hydroxyethyl, 3-oxetanoxy, trifluoroethylaminomethyl, N-methyl-N-methoxyethyl-aminomethyl, cyclopropanylmethyl, cyclopropyl, cyclobutoxy, 1-cyclopropanylethoxy, cyclopropanylmethylaminomethyl, 4-methylpiperazin-1-carbonyl, isoindolin-2-yl, N-methoxyethylcarbamoyl, N-(morpholin-4-yl)-ethylcarbamoyl, dimethylaminoethylamino, N,N-dimethylaminoethylcarbamoyl, benzyl, phenylethyl, trifluoromethylphenylethyl, phenoxymethyl, fluorophenoxymethyl, phenylethylaminomethyl, benzylaminomethyl, triazinylmethyl, piperidinylmethyl, piperidinyloxy, trifluoromethylpiperidinylmethyl, pyridinyloxymethyl, pyridinylmethoxy, tetrahydropyrazinyloxy, methylpiperazinylmethyl, methanesulfonyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, pyrrolidin-1-ylethoxy, pyrrolidin-2-ylethoxy, pyrrolidin-3-ylethoxy, thiazol-4-yl, 2-methyl-thiazol-4-yl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-4-ylmethyl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, imidazolidin-1-ylmethyl, imidazolidin-2-ylmethyl, imidazolidin-4-ylmethyl, imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolin-1-yl, pyrazolin-3-yl, pyrazolin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-ylmethyl, piperidin-2-ylmethyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-2-ylmethyl, morpholin-3-ylmethyl, morpholin-4-ylmethyl, morpholin-4-ylsulfonyl, morpholin-2-ylethoxy, morpholin-3-ylethoxy and morpholin-4-ylethoxy; R.sup.5 is H, alkyl or haloalkyl; R.sup.6 is fluoro, chloro, bromo, or methyl and n is 0 or 1; and R.sup.7 is hydroxyl, aryl or heteroaryl, wherein aryl or heteroaryl are substituted with --NH.sub.2 or --OH at a ring position adjacent to attachment of the --CONH-moiety, and R.sup.7 is optionally further substituted with one or more groups selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxy, alkyl, haloalkyl and cycloalkyl. 9. A compound selected from those of Formula (II) and pharmaceutically acceptable salts thereof: ##STR00572## wherein R.sup.2 is selected from the group consisting of H, hydroxy, C.sub.1-10 alkyl, C.sub.1-10 alkanoyl, C.sub.1-10 methoxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, N,N-(C.sub.1-10 alkyl).sub.2aminoalkyl, cyano, carboxyl, methylcarboxyl, N,N-(C.sub.1-10 alkyl).sub.2amide, N,N-(C.sub.1-10 alkyl).sub.2-aminoethylaminocarbonyl, morpholinylsulfonyl, alkylthiazolyl, C.sub.1-10 alkyl-S(O)a wherein a is 0, 1 or 2, morpholinylmethyl and pyrrolidinylmethyl; R.sup.5 is H or alkyl; R.sup.6 is halo and n is 0 or 1; and R.sup.7 is hydroxy, aryl or heteroaryl, wherein aryl or heteroaryl are substituted with --NH.sub.2 at a ring position adjacent to attachment of the --CONH-moiety. 10. A pharmaceutical composition comprising an of one or more compounds of claim 1 and a pharmaceutically-acceptable carrier. 11. The pharmaceutical composition according to claim 10, further comprising one or more anti-cancer agents. 12. The pharmaceutical composition according to claim 11, wherein the one or more anti-cancer agents is selected from the group consisting of cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, colony-stimulating factor, amifostine, lenalidomide, HDAC inhibitor, CDK inhibitor, camptothecin and topotecan. |
Details for Patent 8,344,018
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2028-07-14 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2028-07-14 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2028-07-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2028-07-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2028-07-14 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2028-07-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.